Brad Jordan, PhD Amgen

Dr. Brad Jordan is a Director of Global Regulatory and R&D Policy at Amgen where his role focuses on global technical regulatory policy relating to biologics and biosimilars.

Dr. Jordan joined Amgen in 2006, and prior to his role in the Policy group, spent 10 years in the Discovery Research Organization where he specialized in protein biophysics and drug discovery.

Dr. Jordan received his Ph.D. in Biochemistry from the University of Arkansas-Fayetteville and did his post-doctoral work at St. Jude Children’s Research Hospital where he studied protein biophysics and the molecular mechanisms of pathogenic bacterial infection.

Dr. Jordan serves as the Amgen liaison on biologics/biosimilars to multiple trade organizations, including PhRMA, BIO, IFPMA, and Biosimilars Forum and is currently responsible for assessing the regulatory landscape in the US and other regions relating to the regulation of biologics and biosimilars.